New Medicine Approved by FDA
Advil Dual Action (ibuprofen and acetaminophen) Tablets
Comapny: GlaxoSmithKline Consumer Healthcare LP
Date of Approval: February 28, 2020
Treatment for: Pain
Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain.
FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment - February 28, 2020
Zeposia (ozanimod) Capsules
Comapny: Bristol-Myers Squibb Company
Date of Approval: March 25, 2020
Treatment for: Multiple Sclerosis
Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis - March 26, 2020
Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Extended-Release Tablets
Comapny: Boehringer Ingelheim and Eli Lilly and Company
Date of Approval: January 27, 2020
Treatment for: Diabetes Type 2
Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride) is a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance), the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) and the biguanide metformin hydrochloride indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults - January 27, 2020
Barhemsys (amisulpride) Injection
Comapny: Acacia Pharma
Date of Approval: February 26, 2020
Treatment for: Nausea/Vomiting -- Postoperative
Barhemsys (amisulpride) is a dopamine antagonist for the management of post-operative nausea & vomiting (PONV).
FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting - February 27, 2020